Yi Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi Guo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Zhenyu Wu
School of Public Health, Fudan University, Shanghai, China
2 shared publications - Dan Chen
Department of Biostatistics School of Public Health, Fudan University Shanghai China
1 shared publication - Dongsheng Tu
Canadian Cancer Trials Group, Kingston, ON, Canada
1 shared publication Huijuan Yang
Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China
1 shared publication- Huixun Jia
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
1 shared publication - Huixun Jia
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- 16 April 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (8-9) , e70548
Sensitivity Analysis for Unmeasured Confounding in Causal Mediation Analysis With Survival Outcome
The validity of mediation analysis critically depends on the assumption of no unmeasured confounding, which is typically evaluated through sensitivity analysis. However, existing sensitivity analysis methods for mediation analysis with survival outcomes often rely on the rare outcome assumption and neglect the relationship between exposure and unmeasured confounding. To address this challenge, we developed a sensitivity analysis approach to assess the robustness of mediation results. Specifically, it can assess sensitivity to both mediator‐outcome confounding and confounding involving the exposure in observational studies. Our method innovatively generates a simulated unmeasured confounder from its conditional distribution, constructed through sensitivity parameters such as regression coefficients linking the outcome, mediator, and exposure to the unmeasured confounder. Then the sensitivity of mediation analysis can be evaluated by comparing the results before and after adjusting for the simulated unmeasured confounder. A three‐dimensional visualization tool was developed to visualize the sensitivity of mediation analysis results. We validated our methodology on simulated datasets and further applied it to a real dataset from the China Health and Nutrition Survey (CHNS) to investigate the relationship between obesity and stroke mediated by hypertension. An R package “medsenssurv” has also been developed to facilitate implementation of our proposed method ( https://github.com/Guo‐yi‐y/medsenssurv ).
- 16 April 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (8-9) , e70548
Sensitivity Analysis for Unmeasured Confounding in Causal Mediation Analysis With Survival Outcome
The validity of mediation analysis critically depends on the assumption of no unmeasured confounding, which is typically evaluated through sensitivity analysis. However, existing sensitivity analysis methods for mediation analysis with survival outcomes often rely on the rare outcome assumption and neglect the relationship between exposure and unmeasured confounding. To address this challenge, we developed a sensitivity analysis approach to assess the robustness of mediation results. Specifically, it can assess sensitivity to both mediator‐outcome confounding and confounding involving the exposure in observational studies. Our method innovatively generates a simulated unmeasured confounder from its conditional distribution, constructed through sensitivity parameters such as regression coefficients linking the outcome, mediator, and exposure to the unmeasured confounder. Then the sensitivity of mediation analysis can be evaluated by comparing the results before and after adjusting for the simulated unmeasured confounder. A three‐dimensional visualization tool was developed to visualize the sensitivity of mediation analysis results. We validated our methodology on simulated datasets and further applied it to a real dataset from the China Health and Nutrition Survey (CHNS) to investigate the relationship between obesity and stroke mediated by hypertension. An R package “medsenssurv” has also been developed to facilitate implementation of our proposed method ( https://github.com/Guo‐yi‐y/medsenssurv ).
- 1 June 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (8) , 2181-2188
Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial
Surgery for platinum-sensitive, relapsed ovarian cancer (PSROC) is widely practiced but had contradictory survival outcomes in previous studies. In this multicenter, open-label, phase 3 trial, women with PSROC, and having had one previous therapy and no platinum-based chemotherapy (platinum-free interval) of 6 months or more, were randomly assigned to either the surgery group (182 patients) or the no-surgery group (control) (175 patients). Patients with resectable diseases were eligible according to the international model (iMODEL), combined with a positron emission tomography-computed tomography imaging. Overall survival (OS) and progression-free survival were coprimary endpoints in hierarchical testing, and a significantly longer progression-free survival with surgery was previously reported. Final analysis of OS was planned at data maturity of 59%. Between 19 July 2012 and 3 June 2019, 357 patients were enrolled. Median follow-up was 82.5 months. Median OS was 58.1 months with surgery and 52.1 months for control (hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.61–1.05, P = 0.11). The predefined threshold for statistical significance was not met, but prespecified sensitivity analysis was performed. Overall, 61 of 175 (35%) patients in control had crossed over to surgery following subsequent relapse, and adjusted HR for death in the surgery group compared with control was 0.76, 95% CI 0.58–0.99. In subgroup analysis of relapse sites by imaging, median survival was not estimable in the surgery group and was 69.5 months in control in patients with 60 months in the surgery group as compared with five of 175 (2.9%) patients in the control group. In patients with PSROC, surgery did not increase OS in the intention-to-treat population but resulted in a prolongation of survival following adjustment of crossover. ClinicalTrials.gov registration: NCT01611766.
- 1 June 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (8) , 2181-2188
Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial
Surgery for platinum-sensitive, relapsed ovarian cancer (PSROC) is widely practiced but had contradictory survival outcomes in previous studies. In this multicenter, open-label, phase 3 trial, women with PSROC, and having had one previous therapy and no platinum-based chemotherapy (platinum-free interval) of 6 months or more, were randomly assigned to either the surgery group (182 patients) or the no-surgery group (control) (175 patients). Patients with resectable diseases were eligible according to the international model (iMODEL), combined with a positron emission tomography-computed tomography imaging. Overall survival (OS) and progression-free survival were coprimary endpoints in hierarchical testing, and a significantly longer progression-free survival with surgery was previously reported. Final analysis of OS was planned at data maturity of 59%. Between 19 July 2012 and 3 June 2019, 357 patients were enrolled. Median follow-up was 82.5 months. Median OS was 58.1 months with surgery and 52.1 months for control (hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.61–1.05, P = 0.11). The predefined threshold for statistical significance was not met, but prespecified sensitivity analysis was performed. Overall, 61 of 175 (35%) patients in control had crossed over to surgery following subsequent relapse, and adjusted HR for death in the surgery group compared with control was 0.76, 95% CI 0.58–0.99. In subgroup analysis of relapse sites by imaging, median survival was not estimable in the surgery group and was 69.5 months in control in patients with 60 months in the surgery group as compared with five of 175 (2.9%) patients in the control group. In patients with PSROC, surgery did not increase OS in the intention-to-treat population but resulted in a prolongation of survival following adjustment of crossover. ClinicalTrials.gov registration: NCT01611766.
- Open Access
- 5 March 2024
- Published by Elsevier in Eco-Environment & Health
- Vol. 3 (2) , 192-201
Association between exposure to a mixture of organochlorine pesticides and hyperuricemia in U.S. adults: A comparison of four statistical models
- 5 March 2024
- Published by Elsevier in Eco-Environment & Health
- Vol. 3 (2) , 192-201
Open AccessAssociation between exposure to a mixture of organochlorine pesticides and hyperuricemia in U.S. adults: A comparison of four statistical models